Percheron Therapeutics Limited has released a press release.
ATL1102 for DMD EMA PIP feedback and FDA regulatory progress
Filed with ASX ·
6ix hasn’t read this filing yet.
Percheron Therapeutics Limited on 6ix
Earlier from Percheron Therapeutics
- US FDA Feedback on Type C Meeting for ATL1102 in the US
- Manufacture of ATL1102 clinical supplies for Phase IIb trial
- US FDA Type C Meeting for ATL1102 in DMD
- ATL1102 DMD Paediatric Investigation Plan submitted to EMA
- Half Yearly Report and Half Year Accounts
Later from Percheron Therapeutics
- ANP and MCRI new R&D collaboration for ATL1102
- ANP Updates on US Regulatory Plans for ATL1102 in DMD
- ANP to present new proteomics data at WMS Congress 2021
- New data supports ATL1102s broader clinical potential
- Positive feedback received on Paediatric Investigation Plan
Follow Percheron Therapeutics into a list and get an email when it puts out news.
Follow Percheron Therapeutics